In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards starts trial for new BioPhysio heart valve:

This article was originally published in Clinica

Executive Summary

Edwards Lifesciences has begun a pivotal clinical trial of its next generation BioPhysio aortic valve, which it claims is the only replacement heart valve designed to mimic the physiologic motion of a natural heart valve. The valve combines the haemodynamic performance of a native valve with the ease of implant of a traditional stented valve, says the Irvine, California firm. The clinical trial is a large, multicentre study that will take place in Europe, Canada and the US. Enrolment is expected to last for around 18 months, followed by 12-18 months of post-procedural clinical monitoring and follow-up. Edwards hopes to start selling the device in Europe and Canada in 2008. US sales are expected to start later.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT059643

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel